The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Highlights from ASCO GI 2026: HERIZON-GEA-01, ILUSTRO & BREAKWATER
Moh’d Khushman, MD, Washington University, St. Louis, MO, explores key takeaways from the ASCO 2026 Gastrointestinal Cancers Symposium, including results from the HERIZON-GEA-01 trial (NCT05152147) which evaluated zanidatamab with chemotherapy ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma. In addition Dr Khushman discusses findings from the Phase II ILUSTRO trial (NCT03505320) of first-line zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. In colorectal cancer, the BREAKWATER trial (NCT04607421) of encorafenib + cetuximab + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer, was shared at the meeting, which may represent a new potential standard of care for this patient population. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
